Results 1 to 10 of about 1,302,625 (339)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

New England Journal of Medicine, 2021
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the ...
J. Lopez Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E. Tessier, N. Groves, G. Dabrera, R. Myers, C. Campbell, G. Amirthalingam, Matt Edmunds, M. Zambon, K. Brown, S. Hopkins, M. Chand, M. Ramsay   +18 more
semanticscholar   +1 more source

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Nature, 2023
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients^ 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines ^ 2 , 3 .
Luis A. Rojas, Zachary M. Sethna, K. Soares, C. Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander Chu, Rebecca Yu, A. Chandra, T. Waters, J. Ruan, Masataka Amisaki, Abderezak Zebboudj, Z. Odgerel, George Payne, E. Derhovanessian, F.-J. Müller, I. Rhee, M. Yadav, Anton Dobrin, M. Sadelain, M. Łuksza, Noah Cohen, Laura A Tang, O. Basturk, M. Gönen, S. Katz, R. K. Do, A. Epstein, Parisa Momtaz, Wungki Park, R. Sugarman, A. Varghese, E. Won, A. Desai, Alice C. Wei, M. D'Angelica, T. Kingham, I. Mellman, T. Merghoub, J. Wolchok, U. Şahin, Ö. Türeci, B. Greenbaum, W. Jarnagin, J. Drebin, E. O’Reilly, V. Balachandran   +50 more
semanticscholar   +1 more source

Acknowledgment to Reviewers of Vaccines in 2020

Vaccines, 2021
Peer review is the driving force of journal development, and reviewers are gatekeepers who ensure that Vaccines maintains its standards for the high quality of its published papers [...]
Vaccines Editorial Office
doaj   +1 more source

A Comprehensive Review of mRNA Vaccines

International Journal of Molecular Sciences, 2023
mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low-cost manufacturing.
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, Arun Butreddy, Pavan Nukala, S. Palakurthi, Wahid Khan   +6 more
semanticscholar   +1 more source

Acknowledgment to the Reviewers of Vaccines in 2022

Vaccines, 2023
High-quality academic publishing is built on rigorous peer review [...]
Vaccines Editorial Office
doaj   +1 more source

Retraction: Walach et al. The Safety of COVID-19 Vaccinations—We Should Rethink the Policy. Vaccines 2021, 9, 693

Vaccines, 2021
The journal retracts the article, The Safety of COVID-19 Vaccinations—We Should Rethink the Policy [...]
Vaccines Editorial Office
doaj   +1 more source

Expression of Concern: Walach et al. The Safety of COVID-19 Vaccinations—We Should Rethink the Policy. Vaccines 2021, 9, 693

Vaccines, 2021
The journal is issuing this expression of concern to alert readers to significant concerns regarding the paper cited above [...]
Vaccines Editorial Office
doaj   +1 more source

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Nature reviews. Drug discovery, 2021
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront ...
Namit Chaudhary, D. Weissman, K. Whitehead   +2 more
semanticscholar   +1 more source

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Nature reviews. Immunology, 2021
Where 2020 saw the development and testing of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has seen vaccine rollout in many countries.
J. Tregoning, Katie E. Flight, Sophie Higham, Ziyin Wang, B. F. Pierce   +4 more
semanticscholar   +1 more source

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

New England Journal of Medicine, 2022
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom.
N. Andrews, E. Tessier, J. Stowe, C. Gower, Freja C M Kirsebom, R. Simmons, E. Gallagher, S. Thelwall, N. Groves, G. Dabrera, R. Myers, C. Campbell, G. Amirthalingam, Matt Edmunds, M. Zambon, K. Brown, S. Hopkins, M. Chand, S. Ladhani, M. Ramsay, J. Lopez Bernal   +20 more
semanticscholar   +1 more source